NuvOx presenting at The National Council of Entrepreneurial Tech Transfer (NCET2)

National Council of Entrepreneurial Tech Transfer (NCET2)

National Council of Entrepreneurial Tech Transfer (NCET2)The National Council of Entrepreneurial Tech Transfer (NCET2) is an organization of entrepreneurial universities creating and funding university startups.NCET2 promotes best practices in the creation and funding of university startups by supporting entrepreneurship and providing entrepreneurial education. NCET2 connects investors, economic development organizations, public and private funds and tech transfer professionals in building communities of innovation at universities. NCET2 provides an annual conference for innovation stakeholders to share experiences and create a constructive dialog on how to best work together...

On the first day of the conference, Tuesday, September 17, 2013, Nuvox will be presenting in the second Healthcare / Biotech showcase in the morning.Read More ...

…NuvOx presenting at National Heart, Lung, and Blood Institute San Francisco Innovation Conference

The National Heart, Lung, and Blood Institute (NHLBI) provides global leadership for a research, training, and education program to promote the prevention and treatment of heart, lung, and blood diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives.

The National Heart, Lung, and Blood Institute (NHLBI) provides global leadership for a research, training, and education program to promote the prevention and treatment of heart, lung, and blood diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives.The National Institutes of Health's (NIH) National Heart, Lung, and Blood Institute's (NHLBI) San Francisco Innovation Conference co-hosted by Prescience International, a firm dedicated to accelerating the commercialization and global adoption of science and technology will bring together small businesses, angel investors, venture capitalists, strategic partners, and business leaders from the biotech and pharmaceutical industries on September 10, 2013, at the Genentech Hall at U C San Francisco...

NuvOx focuses on improving oxygenation to body tissues. Its technology is based upon a unique material that transports hundreds of times more oxygen per unit dose than any other material that has been previously studied for this application, including red blood cells... Read More...

Dr. William Culp receives Editor’s Honoree for Laboratory Investigation from the Journal of Vascular Interventional Radiology

The Society of Interventional Radiology

The Society of Interventional RadiologyNuvOx's collaborator, Dr. William Culp, Professor of Radiology and Surgery at the University of Arkansas Medical Center, was honored for experimental work performed with NuvOx's product, NVX-108. Dr. Culp's paper, "Dodecafluoropentane emulsion decreases infarct volume in a rabbit ischemic stroke mole," was selected by the Journal of Vascular Interventional Radiology as an Editor’s Honoree for Laboratory Investigation for all papers published in 2012. In this study administration of NVX-108 three hours following stroke resulted in an 85% reduction in brain damage compared to controls. Employees of NuvOx, Drs. Evan Unger and Jennifer Johnson were co-authors on the study.Read More ...

Yet another innovative cancer treatment development, courtesy of Evan Unger, MD
University of Arizona Cancer Center

UA 2011 Innovator of the yearEvan Unger, MD, has spent the majority of his career on the cutting-edge of cancer research.
As co-leader of The University of Arizona Cancer Center Imaging Program, Dr. Unger is the inventor on more than 100 issued patents and has led the development of three compounds approved by the Food and Drug Administration.
In Dr. Unger's world, there is no such thing as an "untreatable tumor." It's simply a tumor that hasn't been solved, yet.
On Jan. 8, the Arizona Daily Star published a story detailing how Dr. Unger, through his company, NuvOx Pharma, is "planning clinical trials of an injectable drug that can infuse tumors with oxygen to make them more susceptible to radiation treatment." Read more...

Tucson tech: NuvOx drug that aids radiation treatments set for clinical trials
Arizona Daily Star

AZ Daily Star talking with Dr. Evan Unger

AZ Daily Star talking with Dr. Evan UngerNearly two decades ago, University of Arizona radiologist Dr. Evan Unger recognized that an ultrasound imaging contrast agent he pioneered held promise as a way to deliver drugs or therapies to specific areas.
Unger's latest effort: a treatment to make cancer tumors more susceptible to radiation therapy.
His four-year-old Tucson company, NuvOx Pharma, is planning clinical trials of an injectable drug that can infuse tumors with oxygen to make them more susceptible to radiation treatment.
So-called hypoxic, or low-oxygen, tumors are resistant to radiation, and in some cases, chemotherapy said Unger, who in addition to faculty positions at the UA Departments of Medical Imaging and Biomedical Engineering is co-director of the Arizona Cancer Center's Cancer Imaging Program. Read More...

Tucson Biotech Gets a Nod from the National Cancer Institute to Develop a Treatment for Solid Malignant Tumors
PRWeb.com

Dr. Johnson and Dr. Unger are working on NVX-108

Dr. Johnson and Dr. Unger are working on NVX-108NuvOx Pharma, LLC, a biotechnology firm based in Tucson, Arizona, received a grant from the National Cancer Institute (NCI) to fund development of its lead oxygen delivery product, NVX-108. Dr. Jennifer Johnson, Chief Operating Officer of NuvOx, said, "It's not easy for small companies to get a 'leg-up' in this economic climate; thus, we are so pleased that this funding will fully support our team on a project in which we will be able to optimize and preliminarily test our product, NVX-108, against cancer." Read More...